Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from ...

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Logistics providers can considerably ease the challenges of transporting essential and time-sensitive medicines along pharma ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.